FORMULATION AND EVALUATION OF BESIFLOXACIN NON-ERODIBLE OCULAR INSERTS
DOI:
https://doi.org/10.22159/ijap.2022v14i1.43058Keywords:
Besifloxacin, Non-erodible ocular insert, Pullulan, PVP, Eudragit RS-100, etcAbstract
Objective: Ocular inserts offer many advantages over conventional dosage forms, like increased ocular residence, the possibility of releasing a drug at a slow and constant rate, accurate dosing, exclusion of preservatives, and increased shelf life. Besifloxacin is a very important drug for the treatment of infectious conjunctivitis. The present study was aimed to formulate and evaluate Besifloxacin Non-Erodible Ocular Insert using Pullulan and polyvinyl pyrrolidone as a drug reservoir, PEG 400 as a plasticizer, and Eudragit RS-100 as a rate-controlling membrane.
Methods: Central composite design was employed to study the effect of independent variables, i.e., effects of Pullulan amount (X1) and PVP (X2) on the dependent variables, i.e., % moisture absorption and In vitro diffusion rate. After evaluation of all thirteen batches of ocular insert reservoir formulation, BSF2 and BSF4 were selected as a satisfactory formulation and was sandwiched between rate-controlling membrane, which was made up of Eudragit RS-100 (3 and 5%).
Results: The drug content of all formulations was found to be in the range of 95.33 to 99.89 %. In vitro diffusion of Besifloxacin from reservoir formulations (BSF1 to BSF13) was found to be 62.44 to 70.62 %. In vitro diffusion rate of an ocular insert of Besifloxacin can offer benefits such as increasing residence time, prolonging drug release in the eye for 24 h. Eudragit RS-100, as a sustained drug release polymer, showed promising sustained released action.
Conclusion: The study concluded that Besifloxacin non-erodible ocular inserts can be successfully developed using Pullulan and polyvinyl pyrrolidone, which will sustain the release of the drug also reduce the frequency of administration, and thereby may help to improve patient compliance.
Downloads
References
Høvding G. Acute bacterial conjunctivitis. Acta ophthalmol. 2008 Feb;86(1):5-17. doi: 10.1111/j.1600-0420.2007.01006.x, PMID 17970823.
Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008 Jan 1;61(1):111-16. doi: 10.1093/jac/dkm398, PMID 17965029.
Tótoli EG, Salgado HRN. Besifloxacin: a critical review of its characteristics, properties, and analytical methods. Crit Rev Anal Chem. 2018 Mar 4;48(2):132-42. doi: 10.1080/10408347.2018.1429885, PMID 29345957.
Chang MH, Fung HB. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. Clin Ther. 2010 Mar 1;32(3):454-71. doi: 10.1016/j.clinthera.2010.03.013, PMID 20399984.
Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech. 2006 Sep;7(3):67. doi: 10.1208/pt070367, PMID 17025248.
Dawaba AM, Dawaba HM, El-enin ASMA, Khalifa MKA. Fabrication of bioadhesive Ocusert with different polymers: once a day dose. Int J App Pharm. 2018 Nov 7;10(6):309-17. doi: 10.22159/ijap.2018v10i6.28495.
Mallari PL, McCarty DJ, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol. 2001 Jan 1;131(1):131-33. doi: 10.1016/s0002-9394(00)00642-5, PMID 11162991.
Gilhotra RM, Gilhotra N, Mishra DN. Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation. Curr Eye Res. 2009 Dec 1;34(12):1065-73. doi: 10.3109/02713680903340738, PMID 19958126.
El-Gendy NA, Abdelbary GA, El-Komy MH, Saafan AE. Design and evaluation of a bioadhesive patch for topical delivery of gentamicin sulphate. Curr Drug Deliv. 2009 Jan 1;6(1):50-7. doi: 10.2174/156720109787048276, PMID 19418955.
RAO MV, Shyale S. Preparation and evaluation of ocular inserts containing norfloxacin. Turk J Med Sci. 2004 Jul 27;34(4):239-46.
Harikumar SL, Balasubramaniam J, Kumar MT, Pandit JK. In vitro characterization of physically reinforced ocular inserts of indomethacin. ACTA Pharm Sci. 2004;46(1).
Mundada AS, Shrikhande BK. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Dev Ind Pharm. 2006 Jan 1;32(4):443-8. doi: 10.1080/03639040500534101, PMID 16638682.
Sreenivas SA, Hiremath SP, Godbole AM. Ofloxacin ocular inserts: design, formulation and evaluation. Iran J Pharmacol Ther. 2006 Dec 22;5(2):159-62.
Sankar V, Chandrasekaran AK, Durga S, Geetha G, Ravichandran V, Vijayakumar A, Raguraman S. Design and evaluation of diclofenac sodium ophthalmic inserts. Acta Pharm Sci. 2006;48(1).
El-Kamel A, Al-Dosari H, Al-Jenoobi F. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv. 2006 Jan 1;13(1):55-9. doi: 10.1080/10717540500309073, PMID 16401594.
Balasubramaniam J, Srinatha A, Nath G. In vitro microbiological evaluation of polyvinyl alcohol-based ocular inserts of ciprofloxacin hydrochloride. Indian J Pharm Sci. 2006;68(5).
Jayaprakash S, Dachinamoorthi D, Ramkanth S, Nagarajan M, Sangeetha K. Formulation and evaluation of gentamicin sulphate ocuserts. Pharm Rev. 2006:131-4.
Mukherjee P, Manvi FV, Sreenivas SA. Sulphacetamide sodium ocular inserts: design, formulation and evaluation. Indian drugs-BOMBAY 2006;43(9):705.
Vijayendra Swamy SM, Nanjawade BK, Ravichandran M, Manvi FV. Development of sustained ocular drug delivery system for betaxolol. Indian J Pharm Educ Res. 2006;40(3):165.
Gupta A, Sharma SK, Ahuja M. In vitro and in vivo evaluation of gellan based ocular inserts of phenylephrine. Acta Pharm Sci. 2007;49(1).
Eaga CM. In-situ gels-a novel approach for ocular drug delivery. Pharm Lett. 2009;1:21-33.
Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. AAPS PharmSciTech. 2011 Dec;12(4):1335-47. doi: 10.1208/s12249-011-9701-3, PMID 21979886.
Juliano C, Cossu M, Pigozzi P, Rassu G, Giunchedi P. Preparation, in vitro characterization and preliminary in vivo evaluation of buccal polymeric films containing chlorhexidine. AAPS PharmSciTech. 2008;9(4):1153-8. doi: 10.1208/s12249-008-9153-6, PMID 19015998.
Khan S, Ali A, Singhavi D, Yeole P. Controlled ocular delivery of acyclovir through rate-controlling ocular insert of eudragit: a technical note. AAPS PharmSciTech. 2008;9(1):169-73. doi: 10.1208/s12249-008-9032-1.
Niamprem PA, Srinivas SP, Tiyaboonchai WA. Development and characterization of indomethacin-loaded mucoadhesive nanostructured lipid carriers for topical ocular delivery. Int J App Pharm. 2018;10(2):91-6. doi: 10.22159/ijap.2018v10i2.24738.
Shankar V. A textbook of novel drug delivery system. Pharmamed press; 2012. p. 398-401.
Parmar RB, Tank HM. Design formulation and evaluation of reservoir type controlled released moxifloxacin hydrochloride ocular insert. Asian J Res Pharm Sci. 2013;3(1):19-24.
Kalyanwat R, Shrivastava B, Pathak K. Preparation and evaluation of bioadhesive ocular inserts of aceclofenac. Int J Pharm Sci Rev Res. 2016;41(2):207-13.
Jethava JK, Jethava GK. Design, formulation, and evaluation of novel sustain release bioadhesive in-situ gelling ocular inserts of ketorolac tromethamine. Int J Pharm Investig. 2014;4(4):226-32. doi: 10.4103/2230-973X.143131, PMID 25426444.
Al-Saedi ZHF, Alzhrani RM, Boddu SHS. Formulation and in vitro evaluation of cyclosporine-a inserts prepared using hydroxypropyl methylcellulose for treating dry eye disease. J Ocul Pharmacol Ther. 2016;32(7):451-62. doi: 10.1089/jop.2016.0013, PMID 27294697.
Dhanaraju MD, Sivakumar VR, Subhashree R, Bhaskar K. Bioadhesive ocuserts matrix for ophthalmic administration of ciprofloxacin hydrochloride. Indian Drugs. 2002;39(4):222-4.
Khurana G, Arora S, Pawar PK. Ocular insert for sustained delivery of gatifloxacin sesquihydrate: preparation and evaluations. Int J Pharm Investig. 2012 Apr;2(2):70-7. doi: 10.4103/2230-973X.100040, PMID 23119235.
Gilhotra RM, Nagpal K, Mishra DN. Azithromycin novel drug delivery system for ocular application. Int J Pharm Investig. 2011;1(1):22-8. doi: 10.4103/2230-973X.76725, PMID 23071916.
Singh V, Bushetti SS, Raju SA, Ahmad R, Singh M, Ajmal M. Polymeric ocular hydrogels and ophthalmic inserts for controlled release of timolol maleate. J Pharm Bioallied Sci. 2011;3(2):280-5. doi: 10.4103/0975-7406.80773, PMID 21687359.
Published
How to Cite
Issue
Section
Copyright (c) 2022 JAYASHRI A. PATIL
This work is licensed under a Creative Commons Attribution 4.0 International License.
